RT @SKabrajiMD: Thanks @DAVAOnc for a great week full of new learning and connections and renewing old friendships.

The 2025 DAVA Hawaii Breast Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVABreast

Dr. Christos Vaklavas (@huntsmancancer) presents data from I-SPY 2.2:VV1 + cemiplimab inflames the TME, turning immune-cold HER2− breast tumors “hot.”pCR: 42.9% in TNBC & 21% in HR+ immune-negative subtypes. Ongoing trials aim to validate efficacy. #DAVABreast

Dr. @jsparano @MountSinaiNYC discusses targeting the IL-4/IL-4Rα axis with dupilumab may reprogram an immune-suppressive TME and enhance response to PD-1 blockade. Early data show promise in ICI-refractory tumors; trials ongoing in TNBC and early-stage breast cancer. #DAVABreast

Starting Now: Cellular Therapies and Vaccine Strategies .Moderated by: Dr. Vinay Jain .#DAVABreast

ER+ MBC remains challenging due to poor immunotherapy response. Dr. Sherry Shen (@MSKCancerCenter) presents a phase Ib/II trial testing lenvatinib + pembrolizumab ± fulvestrant in patients progressing after ET + CDK4/6i. Primary endpt: ORR; ph II enrollment ongoing. #DAVABreast

The gut microbiome may shape response & toxicity to ICIs. @SaranyaChumsri @MayoClinic highlights emerging data on FMT, probiotics, and targeted modulation strategies to enhance immunotherapy efficacy and manage irAEs, with ongoing trials like VSL#3 & WBF-038 underway. #DAVABreast

Dr. @SaraNunneryMD presents phase Ib/II data on BNT327, a PD-L1 × VEGF bispecific antibody in 1L TNBC. 🧬 Dual blockade enhances immune activation & vessel normalization.📈 Median PFS 13.5 mo; OS at 12 mo80.8%.🌐 Global phase II trial ongoing. #DAVABreast

Dr. Priyanka Sharma (@KUMedCenter) shows in NeoPACT that high angiogenesis in TNBC is linked to lower pCR and shorter EFS, especially in immune-low tumors. Dual PD-1/PD-L1 + VEGF blockade shows promise: ORRs 72% (Ivonescimab) & 78% (BNT327). NeoASPECT now tests this neoadjuvantly

Starting Now: Novel Immune Checkpoint Approaches.Moderated by: @Dr_RShatsky @UCSDHealth .#DAVABreast

OASIS-4 showed elinzanetant reduced VMS within 1 month in HR+ breast cancer patients on endocrine therapy, with safety profile consistent with natural menopause. Dr. Milana Dolezal (@StanfordMed). #DAVABreast

RT @dradityabardia: Fantastic multidisciplinary breast cancer summit organized by @vinaykjain17. Designed to foster conversation, collabora….

#DAVABreast The HOPE study demonstrates how CARG-BC stratifies patients into low (0–5), medium (6–11), and high-risk (≥12) groups for chemo-related toxicity. Findings support personalized treatment discussions in older adults. Dr. @minasedrakmd @UCLA

RT @NeilVasan: Thanks to @DAVAOnc for highlighting our pragmatic direct to pt liquid biopsy study on capivasertib resistance, funded by @AS….

Exercise during chemotherapy is safe: improves QoL, supports treatment adherence, and may reduce toxicity. Dr. Jennifer Matro (@InovaSchar) #DAVABreast

#DAVABreast Early intervention and supportive care are key in managing AIMSS to help maintain adherence to AI therapy while minimizing musculoskeletal toxicity and preserving quality of life. Dr. Norah Lynn Henry (@umichmedicine) discusses management strategies.

Starting Now: Mitigating Toxicities and Improving QOL.Moderated by: Dr. Edith Perez @MayoClinic .#DAVABreast

Dr. Ajay Dhakal (@DhakalAjay, @WilmotCancer) underscores the importance of integrating systemic disease control with CNS therapies to optimize outcomes for patients with breast cancer brain metastases. #DAVABreast

Theranostics combines diagnostic imaging with therapy. 177Lu-FAP-2286 exemplifies this approach, aiming at CAF-rich tumor microenvironments. Dr. Jordi Rodon (@MDAndersonNews) highlights current progress. #DAVABreast

Reshma Jagsi, MD (@reshmajagsi @WinshipatEmory) highlights IDEA showing low recurrence risk with endocrine therapy alone in select ER+/HER2– patients. Longer follow-up will determine if RT can be safely omitted more broadly. #DAVABreast